These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 35363198)

  • 1. Japanese pediatric patient with moderately active ulcerative colitis successfully treated with ustekinumab: A case report.
    Kakiuchi T; Yoshiura M
    Medicine (Baltimore); 2022 Feb; 101(7):e28873. PubMed ID: 35363198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Japanese pediatric patient with refractory steroid-resistant ulcerative colitis successfully treated with Tofacitinib: A case report.
    Kakiuchi T; Yoshiura M
    Medicine (Baltimore); 2022 Nov; 101(45):e31757. PubMed ID: 36397383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One-year outcomes with ustekinumab therapy in infliximab-refractory paediatric ulcerative colitis: a multicentre prospective study.
    Dhaliwal J; McKay HE; Deslandres C; Debruyn J; Wine E; Wu A; Huynh H; Carman N; Crowley E; Church PC; Walters TD; Ricciuto A; Griffiths AM;
    Aliment Pharmacol Ther; 2021 Jun; 53(12):1300-1308. PubMed ID: 33909911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pediatric case of infliximab-resistant ulcerative colitis successfully treated using vedolizumab.
    Fukura S; Takei M; Takeuchi S; Tayama T; Ono A; Ichihara Y; Shichijo K; Suzuki Y; Mori K; Kondo S
    J Med Invest; 2023; 70(1.2):294-297. PubMed ID: 37164738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis.
    Ochsenkühn T; Tillack C; Szokodi D; Janelidze S; Schnitzler F
    United European Gastroenterol J; 2020 Feb; 8(1):91-98. PubMed ID: 32213052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ustekinumab is effective against ulcerative colitis with intestinal stenosis: A case report.
    Liu A; Guo J; Liu H; Xu Y; Wu J; Mao T; Tian Z; Ding X
    Medicine (Baltimore); 2022 Oct; 101(42):e31213. PubMed ID: 36281114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ustekinumab Use in Pediatric Inflammatory Bowel Disease: A French Multicenter Study From the Pediatric GETAID.
    Koudsi M; Martinez-Vinson C; Pigneur B; Willot S; Djamal D; Enaud R; Rebeuh J; Dupont C; Dabadie A; Bertrand V; Hugot JP; Lachaux A; Ruemmele F; Viala J; Duclaux-Loras R; Pédiatrique G
    J Pediatr Gastroenterol Nutr; 2023 Jun; 76(6):763-770. PubMed ID: 36893481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Symptom Improvement of ulceRative colitis after an Induction dose of UStekinumab in Japanese clinical practice (SIRIUS), measured using patient-reported outcomes: a prospective observational study.
    Matsuoka K; Nagano K; Nagasaki S; Murata Y; Hisamatsu T
    BMJ Open; 2022 May; 12(5):e060081. PubMed ID: 35508346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term Efficacy and Safety of Tacrolimus Plus Ustekinumab Combination Therapy in Children With Steroid-refractory Ulcerative Colitis.
    Nambu R; Miyazawa A; Yoshida M; Hara T; Iwama I
    Inflamm Bowel Dis; 2024 Apr; 30(4):686-687. PubMed ID: 38267832
    [No Abstract]   [Full Text] [Related]  

  • 11. Infliximab for pediatric patients with ulcerative colitis: a phase 3, open-label, uncontrolled, multicenter trial in Japan.
    Tajiri H; Arai K; Kagimoto S; Kunisaki R; Hida N; Sato N; Yamada H; Nagano M; Susuta Y; Ozaki K; Kondo K; Hibi T
    BMC Pediatr; 2019 Oct; 19(1):351. PubMed ID: 31607268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ménétrier's disease in a patient with refractory ulcerative colitis: a clinical challenge and review of the literature.
    Rao S; Viola A; Ksissa O; Fries W
    BMJ Case Rep; 2021 Oct; 14(10):. PubMed ID: 34667052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study.
    Ko Y; Paramsothy S; Yau Y; Leong RW
    Aliment Pharmacol Ther; 2021 Aug; 54(3):292-301. PubMed ID: 34151447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab.
    Hu A; Kotze PG; Burgevin A; Tan W; Jess A; Li PS; Kroeker K; Halloran B; Panaccione R; Peyrin-Biroulet L; Ma C; Ananthakrishnan AN
    Clin Gastroenterol Hepatol; 2021 Jul; 19(7):1366-1376.e2. PubMed ID: 32668338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative real-world effectiveness of vedolizumab and ustekinumab for patients with ulcerative colitis: a GETAID multicentre cohort study.
    Meyer A; Fumery M; Peyrin-Biroulet L; Filippi J; Altwegg R; Bouhnik Y; Serrero M; Laharie D; Roblin X; Nachury M; Abitbol V; Cadiot G; Nancey S; Allez M; Gilletta C; Vuitton L; Savoye G; Nahon S; Bourrier A; Buisson A; Bouguen G; Bourreille A; Viennot S; Carbonnel F; Amiot A
    Scand J Gastroenterol; 2022 Dec; 57(12):1454-1462. PubMed ID: 35819361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ustekinumab for steroid-refractory pancolitis in a biologically naive child: A case report and literature review.
    Alhalabi M
    Medicine (Baltimore); 2023 Mar; 102(9):e33061. PubMed ID: 36862878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study.
    Amiot A; Filippi J; Abitbol V; Cadiot G; Laharie D; Serrero M; Altwegg R; Bouhnik Y; Peyrin-Biroulet L; Gilletta C; Roblin X; Pineton de Chambrun G; Vuitton L; Bourrier A; Nancey S; Gornet JM; Nahon S; Bouguen G; Viennot S; Pariente B; Fumery M;
    Aliment Pharmacol Ther; 2020 Jun; 51(11):1039-1046. PubMed ID: 32291786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study.
    Fumery M; Filippi J; Abitbol V; Biron A; Laharie D; Serrero M; Altwegg R; Bouhnik Y; Peyrin-Biroulet L; Gilletta C; Roblin X; Pineton de Chambrun G; Vuitton L; Bourrier A; Nancey S; Gornet JM; Nahon S; Bouguen G; Viennot S; Nachury M; Amiot A
    Aliment Pharmacol Ther; 2021 Oct; 54(7):944-951. PubMed ID: 34296456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histological healing after infliximab induction therapy in children with ulcerative colitis.
    Wiernicka A; Szymanska S; Cielecka-Kuszyk J; Dadalski M; Kierkus J
    World J Gastroenterol; 2015 Oct; 21(37):10654-61. PubMed ID: 26457025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two Strikes but Not Out: Deep Remission of Ulcerative Colitis with Ustekinumab After Primary Non-response to Infliximab and Vedolizumab.
    Dalal RS; Ananthakrishnan AN; Hamilton MJ; Winter RW
    Dig Dis Sci; 2021 Mar; 66(3):733-737. PubMed ID: 33569666
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.